CUREVAC NV (5CV.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:5CV - NL0015436031 - Common Stock
3.396 EUR
-0.1 (-2.92%)
Taking everything into account, 5CV scores 4 out of 10 in our fundamental rating. 5CV was compared to 82 industry peers in the Biotechnology industry. Both the profitability and the financial health of 5CV get a neutral evaluation. Nothing too spectacular is happening here. 5CV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
5CV had positive earnings in the past year.
In the past year 5CV has reported a negative cash flow from operations.
5CV had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: 5CV reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 11.31%, 5CV belongs to the best of the industry, outperforming 82.93% of the companies in the same industry.
5CV's Return On Equity of 14.79% is amongst the best of the industry. 5CV outperforms 82.93% of its industry peers.
5CV has a better Return On Invested Capital (14.12%) than 87.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROIC | 14.12% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 182.11%, 5CV belongs to the best of the industry, outperforming 97.56% of the companies in the same industry.
5CV has a better Operating Margin (212.01%) than 98.78% of its industry peers.
5CV has a better Gross Margin (93.01%) than 87.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
5CV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, 5CV has about the same amount of shares outstanding.
The number of shares outstanding for 5CV has been increased compared to 5 years ago.
5CV has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.97 indicates that 5CV is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.97, 5CV is doing good in the industry, outperforming 75.61% of the companies in the same industry.
A Debt/Equity ratio of 0.03 indicates that 5CV is not too dependend on debt financing.
5CV has a Debt to Equity ratio of 0.03. This is in the better half of the industry: 5CV outperforms 64.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.97 |
ROIC/WACC1.97
WACC7.18%
2.3 Liquidity
5CV has a Current Ratio of 3.70. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
5CV has a Current ratio of 3.70. This is in the better half of the industry: 5CV outperforms 69.51% of its industry peers.
A Quick Ratio of 3.69 indicates that 5CV has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.69, 5CV is doing good in the industry, outperforming 73.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.83% over the past year.
5CV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.98%.
The Revenue has been growing by 98.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)20.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
3.2 Future
Based on estimates for the next years, 5CV will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
Based on estimates for the next years, 5CV will show a very negative growth in Revenue. The Revenue will decrease by -10.88% on average per year.
EPS Next Y-170.56%
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-86.75%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 5.86, which indicates a rather cheap valuation of 5CV.
Compared to the rest of the industry, the Price/Earnings ratio of 5CV indicates a rather cheap valuation: 5CV is cheaper than 95.12% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.61. 5CV is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for 5CV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.86 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 5CV is valued cheaply inside the industry as 95.12% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.39 |
4.3 Compensation for Growth
A cheap valuation may be justified as 5CV's earnings are expected to decrease with -28.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
5CV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:5CV (12/22/2025, 7:00:00 PM)
3.396
-0.1 (-2.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.45%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap764.68M
Revenue(TTM)70.74M
Net Income(TTM)128.82M
Analysts73.33
Price Target4.12 (21.32%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)557.4%
Min EPS beat(2)-39.67%
Max EPS beat(2)1154.47%
EPS beat(4)2
Avg EPS beat(4)282.88%
Min EPS beat(4)-39.67%
Max EPS beat(4)1154.47%
EPS beat(8)3
Avg EPS beat(8)141.82%
EPS beat(12)5
Avg EPS beat(12)87.36%
EPS beat(16)8
Avg EPS beat(16)76.39%
Revenue beat(2)1
Avg Revenue beat(2)149.77%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)396.01%
Revenue beat(4)2
Avg Revenue beat(4)82.72%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)396.01%
Revenue beat(8)5
Avg Revenue beat(8)103.01%
Revenue beat(12)5
Avg Revenue beat(12)58%
Revenue beat(16)8
Avg Revenue beat(16)71.24%
PT rev (1m)-3%
PT rev (3m)-2.05%
EPS NQ rev (1m)966.6%
EPS NQ rev (3m)404.74%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.12%
Revenue NQ rev (1m)33.33%
Revenue NQ rev (3m)34.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.86 | ||
| Fwd PE | N/A | ||
| P/S | 10.81 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.88 | ||
| P/tB | 0.9 | ||
| EV/EBITDA | 2.39 |
EPS(TTM)0.58
EY17.08%
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0.31
BVpS3.87
TBVpS3.76
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROCE | 16.62% | ||
| ROIC | 14.12% | ||
| ROICexc | 26.37% | ||
| ROICexgc | 27.79% | ||
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% | ||
| FCFM | N/A |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 28.09% | ||
| Cap/Sales | 7.01% | ||
| Interest Coverage | 66.45 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 | ||
| Altman-Z | 3.97 |
F-Score3
WACC7.18%
ROIC/WACC1.97
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.33%
EPS Next Y-170.56%
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
Revenue Next Year-86.75%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
EBIT growth 1Y13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-158.29%
EBIT Next 3Y-29.43%
EBIT Next 5Y10.78%
FCF growth 1Y62.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / 5CV.DE FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 4 / 10 to 5CV.DE.
Can you provide the valuation status for CUREVAC NV?
ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (5CV.DE). This can be considered as Overvalued.
What is the profitability of 5CV stock?
CUREVAC NV (5CV.DE) has a profitability rating of 5 / 10.
What is the financial health of CUREVAC NV (5CV.DE) stock?
The financial health rating of CUREVAC NV (5CV.DE) is 6 / 10.